MOMO'S BREAKOUT BOARD

[HiddenGem69]

$NVLX The FDA approval of the ABRAXANE-gemcitabine combination is the first new treatment to be approved for adenocarcinoma of the pancreas in nearly eight years and now replaces the gemcitabine-TARCEVA (erlotinib) combination, which was approved in 2005, as first-line therapy. Prior to that latter approval, single-agent gemcitabine, also known as GEMZAR®, had been the treatment of choice (the "gold standard") for the disease since its approval by the FDA in 1996.